Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for David F Hale. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at David F Hale har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:DRMA / Dermata Therapeutics, Inc. | Director | 80.957 |
US:ONCT / Oncternal Therapeutics, Inc. | Director | 29.673 |
US:BIOC / Biocept Inc | Director | 796 |
US:CNAT / Conatus Pharmaceuticals Inc. | Director | 45.000 |
US:SNTS / Santarus, Inc | Director | 0 |
US:SOMX / Somaxon Pharmaceuticals, Inc. | Director | 0 |
Director | 0 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af David F Hale. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb DRMAW / Dermata Therapeutics, Inc. - Equity Warrant – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i DRMAW / Dermata Therapeutics, Inc. - Equity Warrant. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-08-17 | DRMA | HALE DAVID F | 35.714 | 2.613 | 78 | 1500 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg DRMAW / Dermata Therapeutics, Inc. - Equity Warrant – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i DRMAW / Dermata Therapeutics, Inc. - Equity Warrant. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb HSTOQ / Histogen Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i DRMAW / Dermata Therapeutics, Inc. - Equity Warrant. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2013-07-30 | CNAT | HALE DAVID F | 2.588 | 11,0000 | 2.588 | 11,0000 | 28.468 | 164 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg HSTOQ / Histogen Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i DRMAW / Dermata Therapeutics, Inc. - Equity Warrant. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af David F Hale som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-01-23 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
A - Award | 78.741 | 80.957 | 3.553,29 | ||||
2024-02-27 |
|
4 | ONCT |
Oncternal Therapeutics, Inc.
Common Stock |
P - Purchase | 266 | 29.673 | 0,90 | 9,04 | 2.405 | 268.244 | |
2024-02-27 |
|
4 | ONCT |
Oncternal Therapeutics, Inc.
Common Stock |
P - Purchase | 714 | 714 | 9,04 | 6.455 | 6.455 | ||
2022-10-07 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
A - Award | 30.155 | 75.720 | 66,18 | ||||
2022-07-08 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
A - Award | 26.441 | 45.565 | 138,26 | ||||
2022-04-08 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
A - Award | 15.466 | 19.124 | 422,80 | ||||
2022-02-11 |
|
5 | ONCT |
Oncternal Therapeutics, Inc.
Common Stock |
G - Gift | -125.000 | 588.152 | -17,53 | ||||
2022-01-05 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 5.000 | 5.000 | |||||
2021-12-10 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
S - Sale | -71 | 796 | -8,19 | 4,07 | -289 | 3.237 | |
2021-12-10 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
S - Sale | -11 | 101 | -9,82 | 4,07 | -45 | 411 | |
2021-12-10 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
S - Sale | -363 | 3.114 | -10,44 | 4,06 | -1.474 | 12.643 | |
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Warrant to Purchase Common Stock |
P - Purchase | 35.714 | 35.714 | |||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Warrant to Purchase Common Stock |
C - Conversion | 3.048 | 3.048 | |||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Series 1a Warrants |
C - Conversion | -62.500 | 0 | -100,00 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -555.622 | 0 | -100,00 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Series 1c Preferred Stock |
C - Conversion | -3.571.428 | 0 | -100,00 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Series 1b Preferred Stock |
C - Conversion | -410.000 | 0 | -100,00 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Series 1a Preferred Stock |
C - Conversion | -250.000 | 0 | -100,00 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Series 1d Preferred Stock |
C - Conversion | -302.112 | 0 | -100,00 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
P - Purchase | 35.714 | 35.714 | |||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
C - Conversion | 27.103 | 532.925 | 5,36 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
C - Conversion | 174.216 | 505.822 | 52,54 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
C - Conversion | 20.000 | 331.606 | 6,42 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
C - Conversion | 12.195 | 311.606 | 4,07 | ||||
2021-08-17 |
|
4 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
C - Conversion | 44.777 | 299.411 | 17,58 | ||||
2021-08-12 | 3 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
3.658 | ||||||||
2021-08-12 | 3 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
12.195 | ||||||||
2021-08-12 | 3 | DRMA |
Dermata Therapeutics, Inc.
Common Stock |
254.634 | ||||||||
2021-07-20 |
|
4 | BIOC |
BIOCEPT INC
Employee Stock Option (right to buy) |
A - Award | 10.000 | 10.000 | |||||
2021-07-02 |
|
4 | ONCT |
Oncternal Therapeutics, Inc.
Common Stock |
S - Sale | -3.669 | 713.152 | -0,51 | 4,75 | -17.428 | 3.387.472 | |
2021-05-27 |
|
4 | ONCT |
Oncternal Therapeutics, Inc.
Stock Options |
A - Award | 37.500 | 37.500 | |||||
2020-07-31 |
|
4/A | ONCT |
Oncternal Therapeutics, Inc.
Stock Option |
A - Award | 22.500 | 22.500 | |||||
2020-07-31 |
|
4/A | ONCT |
Oncternal Therapeutics, Inc.
Stock Option |
A - Award | 40.000 | 40.000 | |||||
2020-06-12 |
|
4 | ONCT |
Oncternal Therapeutics, Inc.
Stock Options |
A - Award | -22.500 | 22.500 | -50,00 | ||||
2020-06-12 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
S - Sale | -556 | 867 | -39,07 | 0,56 | -309 | 481 | |
2020-06-12 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
S - Sale | -445 | 112 | -79,89 | 0,55 | -247 | 62 | |
2020-06-12 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
S - Sale | -159 | 3.477 | -4,37 | 0,56 | -89 | 1.939 | |
2020-06-09 |
|
4 | BIOC |
BIOCEPT INC
Employee Stock Option (right to buy) |
A - Award | 500 | 500 | |||||
2020-05-22 |
|
4 | ONCT |
Oncternal Therapeutics, Inc.
Warrants |
P - Purchase | 8.706 | 8.706 | |||||
2020-05-22 |
|
4 | ONCT |
Oncternal Therapeutics, Inc.
Common Stock |
P - Purchase | 17.412 | 716.818 | 2,49 | ||||
2019-09-16 |
|
4 | ONCT |
Oncternal Therapeutics, Inc.
Stock Option |
A - Award | -40.000 | 40.000 | -50,00 | ||||
2019-07-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy) |
A - Award | 45.000 | 45.000 | |||||
2019-06-19 |
|
4 | BIOC |
BIOCEPT INC
Employee Stock Option (right to buy) |
A - Award | 500 | 500 | |||||
2019-06-19 |
|
4 | BIOC |
BIOCEPT INC
Employee Stock Option (right to buy) |
A - Award | 30.000 | 30.000 | |||||
2019-06-11 |
|
4 | ONCT |
GTX INC /DE/
Warrants |
A - Award | 3.292 | 3.292 | |||||
2019-06-11 |
|
4 | ONCT |
GTX INC /DE/
Common Stock |
A - Award | 18.346 | 18.346 | |||||
2019-06-11 |
|
4 | ONCT |
GTX INC /DE/
Common Stock |
A - Award | 699.406 | 699.406 | |||||
2018-07-02 |
|
4 | BIOC |
BIOCEPT INC
Employee Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
2018-06-25 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy) |
A - Award | 45.000 | 45.000 | |||||
2017-06-26 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy) |
A - Award | 45.000 | 45.000 | |||||
2017-06-02 |
|
4 | BIOC |
BIOCEPT INC
Employee Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
2017-04-03 |
|
4 | BIOC |
BIOCEPT INC
Employee Stock Option (right to buy) |
A - Award | 4.166 | 4.166 | |||||
2016-10-21 |
|
4 | BIOC |
BIOCEPT INC
Warrant to Purchase Common Stock |
P - Purchase | 90.909 | 90.909 | |||||
2016-10-21 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
P - Purchase | 90.909 | 109.099 | 499,77 | 1,10 | 100.000 | 120.009 | |
2016-10-21 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
G - Gift | 13.334 | 16.736 | 391,95 | ||||
2016-10-21 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
G - Gift | -13.334 | 18.190 | -42,30 | ||||
2016-10-21 | 3/A | BIOC |
BIOCEPT INC
Common Stock |
10.204 | ||||||||
2016-06-24 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy) |
A - Award | 45.000 | 45.000 | |||||
2016-05-05 |
|
4 | BIOC |
BIOCEPT INC
Warrant to Purchase Common Stock |
P - Purchase | 35.000 | 35.000 | |||||
2016-05-05 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
P - Purchase | 50.000 | 138.356 | 56,59 | 1,00 | 50.000 | 138.356 | |
2016-01-04 |
|
4 | BIOC |
BIOCEPT INC
Stock Option (right to buy) |
A - Award | 12.500 | 12.500 | |||||
2015-11-10 |
|
4 | BIOC |
BIOCEPT INC
Restricted Stock Units |
M - Exercise | -53.662 | 0 | -100,00 | ||||
2015-11-10 |
|
4 | BIOC |
BIOCEPT INC
Restricted Stock Units |
M - Exercise | -10.204 | 0 | -100,00 | ||||
2015-11-10 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
M - Exercise | 53.662 | 88.356 | 154,67 | ||||
2015-11-10 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
M - Exercise | 10.204 | 34.694 | 41,67 | ||||
2015-08-25 |
|
4 | BIOC |
BIOCEPT INC
Restricted Stock Units |
M - Exercise | -14.286 | 0 | -100,00 | ||||
2015-08-25 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
M - Exercise | 14.286 | 24.490 | 140,00 | ||||
2015-06-15 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc.
Stock Option (Right to Buy) |
A - Award | 35.000 | 35.000 | |||||
2015-02-18 |
|
4 | BIOC |
BIOCEPT INC
Warrant to Purchase Common Stock |
P - Purchase | 40.000 | 40.000 | |||||
2015-02-18 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
P - Purchase | 40.000 | 94.570 | 73,30 | 1,25 | 50.000 | 118.212 | |
2014-06-23 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Stock Option (Right to Buy) |
A - Award | 35.000 | 35.000 | |||||
2014-02-24 |
|
4 | BIOC |
BIOCEPT INC
Stock Options (right to buy) |
A - Award | 53.108 | 53.108 | |||||
2014-02-18 |
|
4 | BIOC |
BIOCEPT INC
Stock Options (right to buy) |
A - Award | 70.000 | 70.000 | |||||
2014-02-12 |
|
4 | BIOC |
BIOCEPT INC
Warrants (right to buy) |
J - Other | 36.302 | 36.302 | |||||
2014-02-12 |
|
4 | BIOC |
BIOCEPT INC
Warrants (right to buy) |
J - Other | 22.175 | 22.175 | |||||
2014-02-12 |
|
4 | BIOC |
BIOCEPT INC
Issuer?s repurchase right (obligation to sell) |
E - Other | -10.204 | 0 | -100,00 | 4,62 | -47.142 | ||
2014-02-12 |
|
4 | BIOC |
BIOCEPT INC
Restricted Stock Units (right to buy) |
J - Other | 53.662 | 53.662 | |||||
2014-02-12 |
|
4 | BIOC |
BIOCEPT INC
Restricted Stock Units (right to buy) |
J - Other | 10.204 | 10.204 | |||||
2014-02-12 |
|
4 | BIOC |
BIOCEPT INC
Convertible Notes (right to buy) |
C - Conversion | -47.181 | 0 | -100,00 | ||||
2014-02-12 |
|
4 | BIOC |
BIOCEPT INC
Common Stock |
C - Conversion | 47.181 | 54.570 | 638,53 | 10,00 | 471.810 | 545.700 | |
2014-02-04 | 3 | BIOC |
BIOCEPT INC
Common Stock |
10.204 | ||||||||
2014-02-04 | 3 | BIOC |
BIOCEPT INC
Common Stock |
7.389 | ||||||||
2014-01-10 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Stock Option (Right to Buy) |
M - Exercise | -12.121 | 0 | -100,00 | ||||
2014-01-10 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
M - Exercise | 12.121 | 24.242 | 100,00 | 0,99 | 12.000 | 24.000 | |
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -10.000 | 0 | -100,00 | 22,55 | -225.500 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -25.000 | 0 | -100,00 | 23,00 | -575.000 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -25.000 | 0 | -100,00 | 22,00 | -550.000 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -25.000 | 0 | -100,00 | 29,00 | -725.000 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -40.000 | 0 | -100,00 | 25,27 | -1.010.800 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -42.000 | 0 | -100,00 | 26,68 | -1.120.560 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -32.000 | 0 | -100,00 | 28,67 | -917.440 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -42.000 | 0 | -100,00 | 28,88 | -1.212.960 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -42.000 | 0 | -100,00 | 25,27 | -1.061.340 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -42.000 | 0 | -100,00 | 10,07 | -422.940 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
U - Other | -18.000 | 0 | -100,00 | 32,00 | -576.000 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
U - Other | -5.000 | 0 | -100,00 | 32,00 | -160.000 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
U - Other | -164.713 | 0 | -100,00 | 32,00 | -5.270.816 | ||
2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
U - Other | -130.739 | 0 | -100,00 | 32,00 | -4.183.648 | ||
2013-09-27 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Stock Option (Right to Buy) |
M - Exercise | -12.121 | 0 | -100,00 | ||||
2013-09-27 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
M - Exercise | 12.121 | 12.121 | 2,31 | 28.000 | 28.000 | ||
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Stock Option (Right to Buy) |
A - Award | 50.000 | 50.000 | |||||
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Series A Preferred Stock |
C - Conversion | -162.356 | 0 | -100,00 | ||||
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
P - Purchase | 2.588 | 143.739 | 1,83 | 11,00 | 28.468 | 1.581.129 | |
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
J - Other | 261 | 141.151 | 0,19 | 11,00 | 2.871 | 1.552.661 | |
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
C - Conversion | 19.679 | 140.890 | 16,24 | ||||
2013-07-24 | 3 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
121.211 | ||||||||
2013-06-12 |
|
4 | SNTS |
SANTARUS INC
Stock Option (right to buy) |
A - Award | 42.000 | 42.000 | |||||
2013-03-08 |
|
4 | SOMX |
Pernix Sleep, Inc.
Common Stock |
D - Sale to Issuer | -40.098 | 0 | -100,00 | ||||
2013-03-08 |
|
4 | SOMX |
Pernix Sleep, Inc.
Common Stock |
D - Sale to Issuer | -70.388 | 0 | -100,00 | ||||
2013-01-03 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
A - Award | 16.033 | 70.388 | 29,50 | ||||
2012-12-13 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -42.000 | 0 | -100,00 | ||||
2012-12-13 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -42.000 | 0 | -100,00 | ||||
2012-12-13 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 42.000 | 304.452 | 16,00 | 2,47 | 103.740 | 751.996 | |
2012-12-13 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 42.000 | 262.452 | 19,05 | 2,02 | 84.840 | 530.153 | |
2012-10-02 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
A - Award | 137.586 | 434.845 | 46,28 | ||||
2012-07-03 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
A - Award | 144.951 | 297.259 | 95,17 | ||||
2012-06-14 |
|
4 | SNTS |
SANTARUS INC
Stock Option (right to buy) |
A - Award | 42.000 | 42.000 | |||||
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Stock Option (right to buy) |
A - Award | 40.000 | 40.000 | |||||
2012-04-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
A - Award | 152.308 | 152.308 | |||||
2012-04-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
G - Gift | -2.200 | 320.787 | -0,68 | ||||
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -42.000 | 0 | -100,00 | ||||
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -32.000 | 0 | -100,00 | ||||
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -4.285 | 0 | -100,00 | ||||
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -11.428 | 0 | -100,00 | ||||
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 2.000 | 18.000 | 12,50 | 5,34 | 10.675 | 96.071 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 4.000 | 16.000 | 33,33 | 5,34 | 21.380 | 85.520 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 1.000 | 12.000 | 9,09 | 5,34 | 5.340 | 64.080 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 2.000 | 11.000 | 22,22 | 5,34 | 10.676 | 58.716 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 1.000 | 9.000 | 12,50 | 5,35 | 5.352 | 48.172 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 1.000 | 8.000 | 14,29 | 5,35 | 5.350 | 42.800 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 5.779 | 7.000 | 473,30 | 5,34 | 30.880 | 37.404 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 1.221 | 1.221 | 5,34 | 6.521 | 6.521 | ||
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 42.000 | 220.452 | 23,54 | 2,38 | 99.960 | 524.676 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 32.000 | 178.452 | 21,85 | 1,18 | 37.760 | 210.573 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 4.285 | 146.452 | 3,01 | 1,22 | 5.249 | 179.404 | |
2012-03-22 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 11.428 | 142.167 | 8,74 | 0,88 | 10.000 | 124.396 | |
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -50.000 | 0 | -100,00 | 5,47 | -273.500 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -30.000 | 0 | -100,00 | 4,11 | -123.300 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -150.000 | 0 | -100,00 | 4,34 | -651.000 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -30.000 | 0 | -100,00 | 6,49 | -194.700 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -150.000 | 0 | -100,00 | 7,84 | -1.176.000 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -30.000 | 0 | -100,00 | 8,25 | -247.500 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -30.000 | 0 | -100,00 | 8,67 | -260.100 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -70.000 | 0 | -100,00 | 4,37 | -305.900 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -33.333 | 0 | -100,00 | 2,39 | -79.666 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -50.000 | 0 | -100,00 | 6,56 | -328.000 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -50.000 | 0 | -100,00 | 2,54 | -127.000 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -68.182 | 0 | -100,00 | 1,10 | -75.000 | ||
2012-03-09 |
|
4 | MITI |
MICROMET, INC.
Stock Option (right to buy) |
D - Sale to Issuer | -83.333 | 0 | -100,00 | 1,10 | -91.666 | ||
2012-03-06 |
|
4 | MITI |
MICROMET, INC.
Common Stock |
U - Other | -18.165 | 0 | -100,00 | 11,00 | -199.815 | ||
2012-03-06 |
|
4 | MITI |
MICROMET, INC.
Common Stock |
U - Other | -103.786 | 0 | -100,00 | 11,00 | -1.141.646 |